Epithelial-restricted gene profile of primary cultures from human prostate tumors: A molecular approach to predict clinical behavior of prostate cancer

Molecular Cancer Research

Volumn 4, Issue 2, 2006, Pages 79-92

  Nanni, Simona ^a   Priolo, Carmen ^a,c,d   Grasselli, Annalisa ^a,b   D'Eletto, Manuela ^a   Merola, Roberta ^a   Moretti, Fabiola ^a,c   Gallucci, Michele ^a   De Carli, Piero ^a   Sentinelli, Steno ^a   Cianciulli, Anna Maria ^a   Mottolese, Marcelle ^a   Carlini, Paolo ^a   Arcelli, Diego ^b   Helmer Citterich, Mauro ^b   Gaetano, Carlo ^b   Loda, Massimo ^d   Pontecorvi, Alfredo ^a,b   Bacchetti, Silvia ^a   Sacchi, Ada ^a   Farsetti, Antonella ^a,c  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c CNR   (Italy)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; ARTICLE; CELL CULTURE; CELL ISOLATION; CELL POPULATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; CELL DIFFERENTIATION; CELLS, CULTURED; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 33645123129     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0098     Document Type: Article

References (52)

1. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;50:125-8.
2. Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 1975;2:105-24.
3. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
4. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9.
5. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
6. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113:913-23.
7. Luo J, Duggan DJ, Chen Y, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61:4683-8.
8. Yu YP, Landsittel D, Jing L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22:2790-9.
9. Rubin MA, De Marzo AM. Molecular genetics of human prostate cancer. Mod Pathol 2004;17:380-8.
10. Peehl DM. Are primary cultures realistic models of prostate cancer? J Cell Biochem 2004;91:185-95.
11. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000;14:2410-34.
12. Peehl DM. Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer 2005;12:19-47.
13. He WW, Sciavolino PJ, Wing J, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997;43:69-77.
14. Di Lorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44.
15. Tsuchiya N, Slezak JM, Lieber MM, Bergstralh EJ, Jenkins RB. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer 2002;34:363-71.
16. Isaacs W, De Marzo A, Nelson WG. Focus on prostate cancer. Cancer Cell 2002;2:113-6.
17. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
18. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res 1996;56:218-22.
19. Fong CJ, Sherwood ER, Sutkowski DM, et al. Reconstituted basement membrane promotes morphological and functional differentiation of primary human prostatic epithelial cells. Prostate 1991;19:221-35.
20. Garraway LA, Lin D, Signoretti S, et al. Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate 2003;55:206-18.
21. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines. Part 2. J Urol 2005;173:360-72.
22. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines. Part 1. J Urol 2005;173:342-59.
23. Ko D, Gu Y, Yasunaga Y, et al. A novel neoplastic primary tumor-derived human prostate epithelial cell line. Int J Oncol 2003;22:1311-7.
24. Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 2003;115:145-67.
25. Dairkee SH, Ji Y, Ben Y, Moore DH, Meng Z, Jeffrey SS. A molecular "signature" of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics 2004;5:47.
26. Calvo A, Xiao N, Kang J, et al. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res 2002;62:5325-35.
27. Jetzt A, Howe JA, Horn MT, et al. Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice. Cancer Res 2003;63:6697-706.
28. van der Poel HG. Smart drugs in prostate cancer. Eur Urol 2004;45:1-17.
29. Hidalgo M. New target, new drug, old paradigm. J Clin Oncol 2004;22:2270-2.
30. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601.
31. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
32. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13.
33. Gu W, Malik S, Ito M, et al. A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation. Mol Cell 1999;3:97-108.
34. Li S, Huang S, Peng SB. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol 2005;27:1329-39.
35. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
36. Cianciulli AM, Leonardo C, Guadagni F, et al. Genetic instability in superficial bladder cancer and adjacent mucosa: an interphase cytogenetic study. Hum Pathol 2003;34:214-21.
37. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 1997;25:2595-7.
38. Nanni S, Narducci M, Della Pietra L, et al. Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest 2002;110:219-27.
39. Uzgare AR, Xu Y, Isaacs JT. In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 2004;91:196-205.
40. Nakatani K, Thompson DA, Barthel A, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-32.
41. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
42. Westfall PH, Young SS. Resampling-based multiple testing: examples and methods for P-value adjustment. New York: Wiley; 1993.
43. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002;99:6567-72.
44. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hall/CRC; 1993.
45. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning. Data mining, interference and prediction. New York:Springer;2001.
46. Volinia S, Evangelisti R, Francioso F, Arcelli D, Carella M, Gasparini P. GOAL: automated Gene Ontology analysis of expression profiles. Nucleic Acids Res 2004;32:W492-9.
47. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003;19:368-75.
48. Efron B, Tibshirani R. Empirical Bayes methods and false discovery rates for microarrays. Genet Epidemiol 2002;23:70-86.
49. Fujio Y, Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 1999;274:16349-54.
50. Gowdak LH, Poliakova L, Wang X, et al. Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 2000;102:565-71.
51. Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5:489-500.
52. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.